Case Report
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Apr 6, 2021; 9(10): 2326-2333
Published online Apr 6, 2021. doi: 10.12998/wjcc.v9.i10.2326
Prolonged use of bedaquiline in two patients with pulmonary extensively drug-resistant tuberculosis: Two case reports
Jing-Tao Gao, Li Xie, Li-Ping Ma, Wei Shu, Li-Jie Zhang, Yu-Jia Ning, Shi-Heng Xie, Yu-Hong Liu, Meng-Qiu Gao
Jing-Tao Gao, Wei Shu, Li-Jie Zhang, Yu-Jia Ning, Shi-Heng Xie, Yu-Hong Liu, Clinical Center on TB, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China
Li Xie, Li-Ping Ma, Meng-Qiu Gao, Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China
Author contributions: Gao JT drafted the manuscript; Xie L and Ma LP collected clinical data of the two cases; Zhang LJ and Ning YJ worked with the drug distribution and management; Shu W and Xie SH were responsible for patient education and management; Gao MQ and Liu YH reviewed and edited the manuscript; The final version of the manuscript was approved by all authors; Gao JT, Xie L, and Ma LP are co-first authors and contributed equally to this case report.
Informed consent statement: This study was approved by the Ethics Committee of Beijing Chest Hospital affiliated with Capital Medical University, and the participant signed a written informed consent to agree with the anonymous use of clinical data.
Conflict-of-interest statement: The authors declared that they have no competing interests.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Meng-Qiu Gao, MD, PhD, Director, Doctor, Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, No. 9 Beiguan Street, Tongzhou District, Beijing 101149, China. gaomengqiu@bjxkyy.cn
Received: October 22, 2020
Peer-review started: October 22, 2020
First decision: December 13, 2020
Revised: December 26, 2020
Accepted: February 4, 2021
Article in press: February 4, 2021
Published online: April 6, 2021
Processing time: 154 Days and 5.8 Hours
Core Tip

Core Tip: In the 2 patients reported here, the longer regimen, including 36-wk bedaquiline treatment, might be an option for patients with extensively drug-resistant tuberculosis. More studies are needed to explore the effectiveness and safety of prolonged use of bedaquiline for 36 wk vs standard 24 wk in the treatment of multidrug-resistant/ extensively drug-resistant tuberculosis and to investigate further the biomarkers and criteria indicative for extension of bedaquline to facilitate clinical use of this novel drug.